{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:26:54Z","timestamp":1791581214467,"version":"4.3.4"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T00:00:00Z","timestamp":1622592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T00:00:00Z","timestamp":1622592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000928","name":"Welch Foundation","doi-asserted-by":"publisher","award":["AU-0042-20030616"],"award-info":[{"award-number":["AU-0042-20030616"]}],"id":[{"id":"10.13039\/100000928","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck & Co., Inc. | Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006945","name":"Texas Emerging Technology Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A conditionally replication-defective human cytomegalovirus (HCMV) vaccine, V160, was shown to be safe and immunogenic in a two-part, double-blind, randomized, placebo-controlled phase I clinical trial (NCT01986010). However, the specificities and functional properties of V160-elicited antibodies remain undefined. Here, we characterized 272 monoclonal antibodies (mAbs) isolated from single memory B cells of six V160-vaccinated subjects. The mAbs bind to diverse HCMV antigens, including multiple components of the pentamer, gB, and tegument proteins. The most-potent neutralizing antibodies target the pentamer-UL subunits. The binding sites of the antibodies overlap with those of antibodies responding to natural HCMV infection. The majority of the neutralizing antibodies target the gHgL subunit. The non-neutralizing antibodies predominantly target the gB and pp65 proteins. Sequence analysis indicated that V160 induced a class of gHgL antibodies expressing the HV1-18\/KV1-5 germline genes in multiple subjects. This study provides valuable insights into primary targets for anti-HCMV antibodies induced by V160 vaccination.<\/jats:p>","DOI":"10.1038\/s41541-021-00342-3","type":"journal-article","created":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T10:20:36Z","timestamp":1622629236000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["A conditionally replication-defective cytomegalovirus vaccine elicits potent and diverse functional monoclonal antibodies in a phase I clinical trial"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1379-1396","authenticated-orcid":false,"given":"Leike","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Freed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7293-9701","authenticated-orcid":false,"given":"Yaping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengsheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane F.","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart P.","family":"Adler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Rupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5666-8622","authenticated-orcid":false,"given":"Dai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4348-2180","authenticated-orcid":false,"given":"Ningyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong-Ming","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9309-2335","authenticated-orcid":false,"given":"Zhiqiang","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,2]]},"reference":[{"key":"342_CR1","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1016\/S1473-3099(17)30143-3","volume":"17","author":"WD Rawlinson","year":"2017","unstructured":"Rawlinson, W. D. et al. Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy. Lancet Infect. Dis. 17, e177\u2013e188 (2017).","journal-title":"Lancet Infect. Dis."},{"key":"342_CR2","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1097\/TP.0b013e3181cee42f","volume":"89","author":"CN Kotton","year":"2010","unstructured":"Kotton, C. N. et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 89, 779\u2013795 (2010).","journal-title":"Transplantation"},{"key":"342_CR3","unstructured":"Mocarski, E. S., Shenk, T., Griffiths, P. D., Pass, R. F. Fields virology, 6th edn. (Wolters Kluwer Health\/Lippincott Williams & Wilkins, 2013)."},{"key":"342_CR4","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1086\/600882","volume":"49","author":"MM Mussi-Pinhata","year":"2009","unstructured":"Mussi-Pinhata, M. M. et al. Birth prevalence and natural history of congenital cytomegalovirus infection in a highly seroimmune population. Clin. Infect. Dis. 49, 522\u2013528 (2009).","journal-title":"Clin. Infect. Dis."},{"key":"342_CR5","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/rmv.535","volume":"17","author":"A Kenneson","year":"2007","unstructured":"Kenneson, A. & Cannon, M. J. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev. Med. Virol. 17, 253\u2013276 (2007).","journal-title":"Rev. Med. Virol."},{"key":"342_CR6","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/S1473-3099(04)01202-2","volume":"4","author":"MK Gandhi","year":"2004","unstructured":"Gandhi, M. K. & Khanna, R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect. Dis. 4, 725\u2013738 (2004).","journal-title":"Lancet Infect. Dis."},{"key":"342_CR7","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1128\/CMR.00062-12","volume":"26","author":"S Manicklal","year":"2013","unstructured":"Manicklal, S., Emery, V. C., Lazzarotto, T., Boppana, S. B. & Gupta, R. K. The \u201csilent\u201d global burden of congenital cytomegalovirus. Clin. Microbiol. Rev. 26, 86\u2013102 (2013).","journal-title":"Clin. Microbiol. Rev."},{"key":"342_CR8","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/j.cell.2014.04.028","volume":"157","author":"MP Weekes","year":"2014","unstructured":"Weekes, M. P. et al. Quantitative temporal viromics: an approach to investigate host-pathogen interaction. Cell 157, 1460\u20131472 (2014).","journal-title":"Cell"},{"key":"342_CR9","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1093\/infdis\/jiz428","volume":"221","author":"CS Nelson","year":"2020","unstructured":"Nelson, C. S. et al. Immune correlates of protection against human cytomegalovirus acquisition, replication, and disease. J. Infect. Dis. 221, S45\u2013S59 (2020).","journal-title":"J. Infect. Dis."},{"key":"342_CR10","doi-asserted-by":"publisher","first-page":"e1007914","DOI":"10.1371\/journal.ppat.1007914","volume":"15","author":"X Ye","year":"2019","unstructured":"Ye, X. et al. Identification of adipocyte plasma membrane-associated protein as a novel modulator of human cytomegalovirus infection. PLoS Pathog. 15, e1007914 (2019).","journal-title":"PLoS Pathog."},{"key":"342_CR11","doi-asserted-by":"crossref","unstructured":"Gerna, G., Kabanova, A., Lilleri, D. Human cytomegalovirus cell tropism and host cell receptors. Vaccines 7, 70 (2019).","DOI":"10.3390\/vaccines7030070"},{"key":"342_CR12","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.cell.2018.06.028","volume":"174","author":"N Martinez-Martin","year":"2018","unstructured":"Martinez-Martin, N. et al. An unbiased screen for human cytomegalovirus identifies neuropilin-2 as a central viral receptor. Cell 174, 1158\u20131171 (2018).","journal-title":"Cell"},{"key":"342_CR13","doi-asserted-by":"publisher","first-page":"16082","DOI":"10.1038\/nmicrobiol.2016.82","volume":"1","author":"A Kabanova","year":"2016","unstructured":"Kabanova, A. et al. Platelet-derived growth factor-alpha receptor is the cellular receptor for human cytomegalovirus gHgLgO trimer. Nat. Microbiol. 1, 16082 (2016).","journal-title":"Nat. Microbiol."},{"key":"342_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9176","volume":"6","author":"S Chandramouli","year":"2015","unstructured":"Chandramouli, S. et al. Structure of HCMV glycoprotein B in the postfusion conformation bound to a neutralizing human antibody. Nat. Commun. 6, 8176 (2015).","journal-title":"Nat. Commun."},{"key":"342_CR15","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1093\/infdis\/161.2.214","volume":"161","author":"WJ Britt","year":"1990","unstructured":"Britt, W. J. & Vugler, L. G. Antiviral antibody responses in mothers and their newborn infants with clinical and subclinical congenital cytomegalovirus infections. J. Infect. Dis. 161, 214\u2013219 (1990).","journal-title":"J. Infect. Dis."},{"key":"342_CR16","doi-asserted-by":"publisher","first-page":"73654","DOI":"10.18632\/oncotarget.18359","volume":"8","author":"L Xia","year":"2017","unstructured":"Xia, L. et al. Active evolution of memory B-cells specific to viral gH\/gL\/pUL128\/130\/131 pentameric complex in healthy subjects with silent human cytomegalovirus infection. Oncotarget 8, 73654\u201373669 (2017).","journal-title":"Oncotarget"},{"key":"342_CR17","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1099\/vir.0.83523-0","volume":"89","author":"G Gerna","year":"2008","unstructured":"Gerna, G. et al. Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial\/epithelial cells, but not fibroblasts, early during primary infection. J. Gen. Virol. 89, 853\u2013865 (2008).","journal-title":"J. Gen. Virol."},{"key":"342_CR18","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1086\/512245","volume":"195","author":"D Lilleri","year":"2007","unstructured":"Lilleri, D. et al. Development of human cytomegalovirus-specific T cell immunity during primary infection of pregnant women and its correlation with virus transmission to the fetus. J. Infect. Dis. 195, 1062\u20131070 (2007).","journal-title":"J. Infect. Dis."},{"key":"342_CR19","doi-asserted-by":"crossref","unstructured":"Lilleri, D. et al. Fetal human cytomegalovirus transmission correlates with delayed maternal antibodies to gH\/gL\/pUL128-130-131 complex during primary infection. PLoS ONE 8, e59863 (2013).","DOI":"10.1371\/journal.pone.0059863"},{"key":"342_CR20","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1016\/j.placenta.2017.04.011","volume":"60","author":"HL Itell","year":"2017","unstructured":"Itell, H. L., Nelson, C. S., Martinez, D. R. & Permar, S. R. Maternal immune correlates of protection against placental transmission of cytomegalovirus. Placenta 60, S73\u2013S79 (2017).","journal-title":"Placenta"},{"key":"342_CR21","doi-asserted-by":"publisher","first-page":"13645","DOI":"10.1073\/pnas.1511526112","volume":"112","author":"KM Bialas","year":"2015","unstructured":"Bialas, K. M. et al. Maternal CD4+ T cells protect against severe congenital cytomegalovirus disease in a novel nonhuman primate model of placental cytomegalovirus transmission. Proc. Natl Acad. Sci. USA 112, 13645\u201313650 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"342_CR22","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1073\/pnas.0409597102","volume":"102","author":"MC Silva","year":"2005","unstructured":"Silva, M. C., Schroer, J. & Shenk, T. Human cytomegalovirus cell-to-cell spread in the absence of an essential assembly protein. Proc. Natl Acad. Sci. USA 102, 2081\u20132086 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"342_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-017-0038-0","volume":"2","author":"F Li","year":"2017","unstructured":"Li, F. et al. Complement enhances in vitro neutralizing potency of antibodies to human cytomegalovirus glycoprotein B (gB) and immune sera induced by gB\/MF59 vaccination. NPJ Vaccines 2, 36 (2017).","journal-title":"NPJ Vaccines"},{"key":"342_CR24","doi-asserted-by":"publisher","first-page":"6267","DOI":"10.1073\/pnas.1800177115","volume":"115","author":"CS Nelson","year":"2018","unstructured":"Nelson, C. S. et al. HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions. Proc. Natl Acad. Sci. USA 115, 6267\u20136272 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"342_CR25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1093\/infdis\/171.1.26","volume":"171","author":"SP Adler","year":"1995","unstructured":"Adler, S. P. et al. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J. Infect. Dis. 171, 26\u201332 (1995).","journal-title":"J. Infect. Dis."},{"key":"342_CR26","doi-asserted-by":"publisher","first-page":"18153","DOI":"10.1073\/pnas.0509201102","volume":"102","author":"D Wang","year":"2005","unstructured":"Wang, D. & Shenk, T. Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc. Natl Acad. Sci. USA 102, 18153\u201318158 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"342_CR27","doi-asserted-by":"publisher","first-page":"362ra145","DOI":"10.1126\/scitranslmed.aaf9387","volume":"8","author":"D Wang","year":"2016","unstructured":"Wang, D. et al. A replication-defective human cytomegalovirus vaccine for prevention of congenital infection. Sci. Transl. Med. 8, 362ra145 (2016).","journal-title":"Sci. Transl. Med."},{"key":"342_CR28","doi-asserted-by":"publisher","first-page":"E4997","DOI":"10.1073\/pnas.1316517110","volume":"110","author":"DC Freed","year":"2013","unstructured":"Freed, D. C. et al. Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine. Proc. Natl Acad. Sci. USA 110, E4997\u2013E5005 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"342_CR29","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/infdis\/jiz141","volume":"220","author":"SP Adler","year":"2019","unstructured":"Adler, S. P. et al. Phase 1 clinical trial of a conditionally replication-defective human cytomegalovirus (CMV) vaccine in CMV-seronegative subjects. J. Infect. Dis. 220, 411\u2013419 (2019).","journal-title":"J. Infect. Dis."},{"key":"342_CR30","doi-asserted-by":"crossref","unstructured":"Liu, Y. et al. A replication-defective human cytomegalovirus vaccine elicits humoral immune responses analogous to those with natural infection. J. Virol. 93, e00747-19 (2019).","DOI":"10.1128\/JVI.00747-19"},{"key":"342_CR31","doi-asserted-by":"publisher","first-page":"e1005230","DOI":"10.1371\/journal.ppat.1005230","volume":"11","author":"C Ciferri","year":"2015","unstructured":"Ciferri, C. et al. Antigenic characterization of the HCMV gH\/gL\/gO and pentamer cell entry complexes reveals binding sites for potently neutralizing human antibodies. PLoS Pathog. 11, e1005230 (2015).","journal-title":"PLoS Pathog."},{"key":"342_CR32","doi-asserted-by":"crossref","unstructured":"Ha, S. et al. Neutralization of diverse human cytomegalovirus strains conferred by antibodies targeting viral gh\/gl\/pul128-131 pentameric complex. J. Virol. 91, e02033-16 (2017).","DOI":"10.1128\/JVI.02033-16"},{"key":"342_CR33","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1128\/JVI.01809-09","volume":"84","author":"A Macagno","year":"2010","unstructured":"Macagno, A. et al. Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH\/gL\/UL128-131A complex. J. Virol. 84, 1005\u20131013 (2010).","journal-title":"J. Virol."},{"key":"342_CR34","doi-asserted-by":"publisher","first-page":"e1005227","DOI":"10.1371\/journal.ppat.1005227","volume":"11","author":"HG Burke","year":"2015","unstructured":"Burke, H. G. & Heldwein, E. E. Crystal structure of the human cytomegalovirus glycoprotein B. PLoS Pathog. 11, e1005227 (2015).","journal-title":"PLoS Pathog."},{"key":"342_CR35","doi-asserted-by":"publisher","first-page":"8209","DOI":"10.1073\/pnas.1404653111","volume":"111","author":"AE Fouts","year":"2014","unstructured":"Fouts, A. E. et al. Mechanism for neutralizing activity by the anti-CMV gH\/gL monoclonal antibody MSL-109. Proc. Natl Acad. Sci. USA 111, 8209\u20138214 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"342_CR36","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/nm.3743","volume":"21","author":"BJ DeKosky","year":"2015","unstructured":"DeKosky, B. J. et al. In-depth determination and analysis of the human paired heavy- and light-chain antibody repertoire. Nat. Med. 21, 86\u201391 (2015).","journal-title":"Nat. Med."},{"key":"342_CR37","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1099\/vir.0.018994-0","volume":"91","author":"DJ Dargan","year":"2010","unstructured":"Dargan, D. J. et al. Sequential mutations associated with adaptation of human cytomegalovirus to growth in cell culture. J. Gen. Virol. 91, 1535\u20131546 (2010).","journal-title":"J. Gen. Virol."},{"key":"342_CR38","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/nature13764","volume":"516","author":"L Pappas","year":"2014","unstructured":"Pappas, L. et al. Rapid development of broadly influenza neutralizing antibodies through redundant mutations. Nature 516, 418\u2013422 (2014).","journal-title":"Nature"},{"key":"342_CR39","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1093\/infdis\/175.3.533","volume":"175","author":"K Schoppel","year":"1997","unstructured":"Schoppel, K., Kropff, B., Schmidt, C., Vornhagen, R. & Mach, M. The humoral immune response against human cytomegalovirus is characterized by a delayed synthesis of glycoprotein-specific antibodies. J. Infect. Dis. 175, 533\u2013544 (1997).","journal-title":"J. Infect. Dis."},{"key":"342_CR40","doi-asserted-by":"publisher","first-page":"17965","DOI":"10.1073\/pnas.1415310111","volume":"111","author":"A Kabanova","year":"2014","unstructured":"Kabanova, A. et al. Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies. Proc. Natl Acad. Sci. USA 111, 17965\u201317970 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"342_CR41","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/0166-0934(88)90113-9","volume":"22","author":"MP Landini","year":"1988","unstructured":"Landini, M. P., Rossier, E. & Schmitz, H. Antibodies to human cytomegalovirus structural polypeptides during primary infection. J. Virol. Methods 22, 309\u2013317 (1988).","journal-title":"J. Virol. Methods"},{"key":"342_CR42","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1007\/s10875-012-9739-3","volume":"32","author":"D Lilleri","year":"2012","unstructured":"Lilleri, D., Kabanova, A., Lanzavecchia, A. & Gerna, G. Antibodies against neutralization epitopes of human cytomegalovirus gH\/gL\/pUL128-130-131 complex and virus spreading may correlate with virus control in vivo. J. Clin. Immunol. 32, 1324\u20131331 (2012).","journal-title":"J. Clin. Immunol."},{"key":"342_CR43","doi-asserted-by":"publisher","first-page":"7043","DOI":"10.1073\/pnas.1814850116","volume":"116","author":"X E","year":"2019","unstructured":"E, X. et al. OR14I1 is a receptor for the human cytomegalovirus pentameric complex and defines viral epithelial cell tropism. Proc. Natl Acad. Sci. USA 116, 7043\u20137052 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"342_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10587-1","volume":"10","author":"KR Stein","year":"2019","unstructured":"Stein, K. R. et al. CD46 facilitates entry and dissemination of human cytomegalovirus. Nat. Commun. 10, 2699 (2019).","journal-title":"Nat. Commun."},{"key":"342_CR45","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1128\/JVI.65.1.138-146.1991","volume":"65","author":"N Kniess","year":"1991","unstructured":"Kniess, N., Mach, M., Fay, J. & Britt, W. Distribution of linear antigenic sites on glycoprotein gp55 of human cytomegalovirus. J. Virol. 65, 138\u2013146 (1991).","journal-title":"J. Virol."},{"key":"342_CR46","doi-asserted-by":"publisher","first-page":"e1002172","DOI":"10.1371\/journal.ppat.1002172","volume":"7","author":"S Potzsch","year":"2011","unstructured":"Potzsch, S. et al. B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies. PLoS Pathog. 7, e1002172 (2011).","journal-title":"PLoS Pathog."},{"key":"342_CR47","doi-asserted-by":"publisher","first-page":"6273","DOI":"10.1073\/pnas.1800224115","volume":"115","author":"I Baraniak","year":"2018","unstructured":"Baraniak, I. et al. Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies. Proc. Natl. Acad. Sci. USA 115, 6273\u20136278 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"342_CR48","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1099\/0022-1317-80-8-2183","volume":"80","author":"A Speckner","year":"1999","unstructured":"Speckner, A., Glykofrydes, D., Ohlin, M. & Mach, M. Antigenic domain 1 of human cytomegalovirus glycoprotein B induces a multitude of different antibodies which, when combined, results in incomplete virus neutralization. J. Gen. Virol. 80, 2183\u20132191 (1999).","journal-title":"J. Gen. Virol."},{"key":"342_CR49","doi-asserted-by":"publisher","first-page":"3982","DOI":"10.3390\/ijms19123982","volume":"19","author":"MM McVoy","year":"2018","unstructured":"McVoy, M. M., Tenorio, E. & Kauvar, L. M. A native human monoclonal antibody targeting HCMV gB (AD-2 Site I). Int. J. Mol. Sci. 19, 3982 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"342_CR50","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1093\/infdis\/jiy102","volume":"217","author":"I Baraniak","year":"2018","unstructured":"Baraniak, I. et al. Epitope-specific humoral responses to human cytomegalovirus glycoprotein-B vaccine with MF59: anti-AD2 levels correlate with protection from viremia. J. Infect. Dis. 217, 1907\u20131917 (2018).","journal-title":"J. Infect. Dis."},{"key":"342_CR51","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.3390\/v6031346","volume":"6","author":"M Zydek","year":"2014","unstructured":"Zydek, M. et al. HCMV infection of human trophoblast progenitor cells of the placenta is neutralized by a human monoclonal antibody to glycoprotein B and not by antibodies to the pentamer complex. Viruses 6, 1346\u20131364 (2014).","journal-title":"Viruses"},{"key":"342_CR52","doi-asserted-by":"crossref","unstructured":"Jenks, J. A. et al. Antibody binding to native cytomegalovirus glycoprotein B predicts efficacy of the gB\/MF59 vaccine in humans. Sci. Transl. Med. 12, eabb3611 (2020).","DOI":"10.1126\/scitranslmed.abb3611"},{"key":"342_CR53","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/nrmicro2548","volume":"9","author":"SA Connolly","year":"2011","unstructured":"Connolly, S. A., Jackson, J. O., Jardetzky, T. S. & Longnecker, R. Fusing structure and function: a structural view of the herpesvirus entry machinery. Nat. Rev. Microbiol. 9, 369\u2013381 (2011).","journal-title":"Nat. Rev. Microbiol."},{"key":"342_CR54","doi-asserted-by":"publisher","first-page":"10923","DOI":"10.1128\/JVI.79.17.10923-10930.2005","volume":"79","author":"L Wu","year":"2005","unstructured":"Wu, L., Borza, C. M. & Hutt-Fletcher, L. M. Mutations of Epstein-Barr virus gH that are differentially able to support fusion with B cells or epithelial cells. J. Virol. 79, 10923\u201310930 (2005).","journal-title":"J. Virol."},{"key":"342_CR55","doi-asserted-by":"crossref","unstructured":"Cui, X. et al. Immunization with human cytomegalovirus core fusion machinery and accessory envelope proteins elicit strong synergistic neutralizing activities. Vaccines 8, 179 (2020).","DOI":"10.3390\/vaccines8020179"},{"key":"342_CR56","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.immuni.2018.03.026","volume":"48","author":"J Snijder","year":"2018","unstructured":"Snijder, J. et al. An antibody targeting the fusion machinery neutralizes dual-tropic infection and defines a site of vulnerability on Epstein-Barr virus. Immunity 48, 799\u2013811 (2018).","journal-title":"Immunity"},{"key":"342_CR57","doi-asserted-by":"publisher","first-page":"3620","DOI":"10.1128\/JVI.03245-12","volume":"87","author":"J Chen","year":"2013","unstructured":"Chen, J., Jardetzky, T. S. & Longnecker, R. The large groove found in the gH\/gL structure is an important functional domain for Epstein-Barr virus fusion. J. Virol. 87, 3620\u20133627 (2013).","journal-title":"J. Virol."},{"key":"342_CR58","doi-asserted-by":"crossref","unstructured":"Tabata, T. et al. Neutralizing monoclonal antibodies reduce human cytomegalovirus infection and spread in developing placentas. Vaccines 7, 135 (2019).","DOI":"10.3390\/vaccines7040135"},{"key":"342_CR59","doi-asserted-by":"publisher","first-page":"11884","DOI":"10.1128\/JVI.01701-15","volume":"89","author":"F Chiuppesi","year":"2015","unstructured":"Chiuppesi, F. et al. Vaccine-Derived Neutralizing Antibodies to the Human Cytomegalovirus gH\/gL Pentamer Potently Block Primary Cytotrophoblast Infection. J. Virol. 89, 11884\u201311898 (2015).","journal-title":"J. Virol."},{"key":"342_CR60","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1038\/emboj.2008.179","volume":"27","author":"CA Thomson","year":"2008","unstructured":"Thomson, C. A. et al. Germline V-genes sculpt the binding site of a family of antibodies neutralizing human cytomegalovirus. EMBO J. 27, 2592\u20132602 (2008).","journal-title":"EMBO J."},{"key":"342_CR61","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1093\/infdis\/jiv448","volume":"213","author":"MM Sajadi","year":"2016","unstructured":"Sajadi, M. M. et al. lambda light chain bias associated with enhanced binding and function of anti-HIV env glycoprotein antibodies. J. Infect. Dis. 213, 156\u2013164 (2016).","journal-title":"J. Infect. Dis."},{"key":"342_CR62","doi-asserted-by":"publisher","first-page":"E2636","DOI":"10.1073\/pnas.1525510113","volume":"113","author":"BJ DeKosky","year":"2016","unstructured":"DeKosky, B. J. et al. Large-scale sequence and structural comparisons of human naive and antigen-experienced antibody repertoires. Proc. Natl Acad. Sci. USA 113, E2636\u2013E2645 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"342_CR63","doi-asserted-by":"publisher","first-page":"8350","DOI":"10.1016\/j.vaccine.2011.08.086","volume":"29","author":"A Tang","year":"2011","unstructured":"Tang, A. et al. A novel high-throughput neutralization assay for supporting clinical evaluations of human cytomegalovirus vaccines. Vaccine 29, 8350\u20138356 (2011).","journal-title":"Vaccine"},{"key":"342_CR64","doi-asserted-by":"publisher","first-page":"15985","DOI":"10.1074\/jbc.M115.652230","volume":"290","author":"JW Loughney","year":"2015","unstructured":"Loughney, J. W. et al. Soluble human cytomegalovirus gH\/gL\/pUL128-131 pentameric complex, but not gH\/gL, inhibits viral entry to epithelial cells and presents dominant native neutralizing epitopes. J. Biol. Chem. 290, 15985\u201315995 (2015).","journal-title":"J. Biol. Chem."},{"key":"342_CR65","doi-asserted-by":"publisher","first-page":"e1007716","DOI":"10.1371\/journal.ppat.1007716","volume":"15","author":"L Li","year":"2019","unstructured":"Li, L. et al. Potent neutralizing antibodies elicited by dengue vaccine in rhesus macaque target diverse epitopes. PLoS Pathog. 15, e1007716 (2019).","journal-title":"PLoS Pathog."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-021-00342-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-021-00342-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-021-00342-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T23:14:37Z","timestamp":1670022877000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-021-00342-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,2]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["342"],"URL":"https:\/\/doi.org\/10.1038\/s41541-021-00342-3","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,2]]},"assertion":[{"value":"22 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.C.F., Y.L., F.L., and D.W. are Merck & Co. employees. Other authors (L.L., D.F.B., W.X., X.Y., S.P.A., R.E.R., N.Z., T.F., Z.A.) declare that there are no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"79"}}